Form 4: Iovance Biotherapeutics Executive Vogt Reports Stock Transactions
SEC Form 4
Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports acquisition of shares through RSU vesting and subsequent disposal to cover tax obligations.
Summary
- On October 14, 2024, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, acquired 20,834 shares of common stock upon the vesting of restricted stock units (RSUs).
- Simultaneously, 8,851 shares were disposed of at a price of $9.77 to satisfy tax withholding requirements related to the RSU vesting.
- Following these transactions, Vogt directly owns 204,245 shares of Iovance Biotherapeutics common stock and 20,835 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions related to executive compensation.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the restricted stock units. |
| October 14, 2024 | Date of RSU vesting and related stock transactions. |
| October 16, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.